Savillex, LLC, based in Eden Prairie, Minnesota, said it has completed its acquisition of Entegris, Inc.’s Life Sciences Fluid Management business. The acquired portfolio covers bioprocessing and pharmaceutical manufacturing solutions, including Aramus and PE bags, single-use assemblies and components used in discovery, clinical and commercial manufacturing.
Savillex said the transaction broadens its life sciences offerings with more high-performance single-use products. The company also gains the Life Sciences Fluid Management team and its technologies in high-purity fluid management. According to Savillex, customers will have access to a wider range of single-use solutions, additional technical expertise and expanded capabilities for applications from early-stage research through commercial manufacturing.
Savillex positions the combination as a way to help customers manage increasingly complex bioprocessing workflows. The company said combining the two businesses’ complementary strengths is intended to deliver greater value and simplify those workflows.
Eric Giesing, chief executive officer of Savillex, said the Life Sciences Fluid Management business had built a strong reputation in high-purity single-use bioprocessing, and he described the Aramus product line as a natural fit alongside Savillex’s existing Savillex, Containment and Bioprocessing offerings. He added that the acquisition expands the company’s portfolio and enables it to offer a broader range of solutions to biopharmaceutical and pharmaceutical customers. Savillex said it will continue investing in technologies intended to help customers accelerate development and production of critical therapies.
Chris Bedi, general manager of Fluid Management at Savillex, said the acquisition creates an opportunity to bring a wider portfolio of high-value fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide. He said the Fluid Management portfolio complements Savillex’s existing capabilities and that the combined organization will continue to provide innovative solutions while expanding support for partners across drug development.
Savillex said the acquisition advances its strategy of delivering industry-leading solutions for the life sciences market. The company said it remains committed to investing in innovation, quality and customer partnerships as it expands its portfolio for biopharmaceutical and pharmaceutical manufacturers. Terms of the transaction were not disclosed. EC M&A of New York served as financial advisor, and Sidley Austin LLP of Chicago served as legal counsel to Savillex.